Clinical Trial Detail

NCT ID NCT01841723
Title Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

hairy cell leukemia

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.